Pair Name | Gambogic acid, Cisplatin | ||
Phytochemical Name | Gambogic acid (PubChem CID: 9852185 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Gambogic acid, Cisplatin | |||
Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
Biological Phenomena | Induction-->Mitochondria-mediated apoptosis | |||
Gene Regulation | Up-regulation | Expression | CASP8 | hsa841 |
Up-regulation | Expression | CASP9 | hsa842 | |
In Vitro Model | MG-63 | Osteosarcoma | Homo sapiens (Human) | CVCL_0426 |
HOS | Osteosarcoma | Homo sapiens (Human) | CVCL_0312 | |
U2OS | Osteosarcoma | Homo sapiens (Human) | CVCL_0042 | |
Result | GA could increase the chemotherapeutic effect of CDDP in human osteosarcoma treatment through inducing the cell cycle arrest and promoting cell apoptosis |
Pair Name | Gambogic acid, Cisplatin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
Gene Regulation | Down-regulation | Expression | ABCC2 | hsa1244 |
Up-regulation | Expression | BAX | hsa581 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Expression | LRP1 | hsa4035 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
Result | Combination of GA with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. |
Pair Name | Gambogic acid, Cisplatin | |||
Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Expression | FAS | hsa355 | |
Up-regulation | Expression | MAPK14 | hsa1432 | |
In Vitro Model | MG-63 | Osteosarcoma | Homo sapiens (Human) | CVCL_0426 |
HOS | Osteosarcoma | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | 0.2 mL of MG63 cell suspension (1.5×10⁷ cells/ml) was subcutaneously injected into the right flank of mice | |||
Result | Our results demonstrate that GA may be a new potent therapeutic agent useful for targeting human OS cells. |
No. | Title | Href |
---|---|---|
1 | Viability inhibition effect of gambogic acid combined with cisplatin on osteosarcoma cells via mitochondria-independent apoptotic pathway. Mol Cell Biochem. 2013 Oct;382(1-2):243-52. doi: 10.1007/s11010-013-1740-5. | Click |
2 | Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Onco Targets Ther. 2016 Jun 2;9:3359-68. doi: 10.2147/OTT.S100936. | Click |
3 | Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α. Mol Cell Biochem. 2016 Sep;420(1-2):1-8. doi: 10.1007/s11010-016-2759-1. | Click |